Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01227616 · ClinicalTrials.gov registry record · Phase 4
Compare Efficacy/Safety of Repeat Doses of Ferumoxytol With Iron Sucrose in CKD Subjects With IDA and on Hemodialysis
A Phase 4 study, sponsored by AMAG Pharmaceuticals.
- Completed
- Registry status
- Phase 4
- Development phase
- 296
- Enrollment target
NCT01227616 is a Phase 4 study that has completed, run by AMAG Pharmaceuticals. The registered enrollment target is 296 participants.
The verdict
NCT01227616, a Phase 4 study, has completed, sponsored by AMAG Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 296 participants
- Enrollment target
Study Summary
The objectives of this study are to compare the efficacy and safety of repeat doses of intravenous (IV) ferumoxytol with IV iron sucrose for the treatment of IDA in subjects with hemodialysis-dependent CKD.
Interventions
- DRUG Ferumoxytol
- DRUG Iron Sucrose
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 296 participants |
| Start Date | 2013-08 |
| Est. Completion | 2017-02 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01227616
The ClinicalTrials.gov registry entry for NCT01227616 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 296 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is AMAG Pharmaceuticals, which has 23 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Ferumoxytol is the first listed.
NCT01227616 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01227616 about?
NCT01227616 is a clinical study titled "Compare Efficacy/Safety of Repeat Doses of Ferumoxytol With Iron Sucrose in CKD Subjects With IDA and on Hemodialysis". The objectives of this study are to compare the efficacy and safety of repeat doses of intravenous (IV) ferumoxytol with IV iron sucrose for the treatment of IDA in subjects with hemodialysis-dependent CKD.
What is the current status of trial NCT01227616?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 296 participants. The study started on 2013-08. Estimated completion is 2017-02.
What interventions are being tested in trial NCT01227616?
The interventions under investigation include: Ferumoxytol (DRUG), Iron Sucrose (DRUG).
Who is sponsoring clinical trial NCT01227616?
This trial is sponsored by AMAG Pharmaceuticals, which has 23 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.